PMR, developed and patented by Sagentia, uses encoded acousto-magnetic labels to create a remote-read identification system.
In the Diprifusor application, a small PMR label, programmed to carry specific information, is attached to the pre-filled drug syringe. When the syringe is inserted into the system’s infusion pump, a reader integrated into the pump body interrogates the PMR label automatically.
The resulting analysis is processed by operating software configured to allow automated drug delivery only if a correct signature is detected. Once the drug has been dispensed at the right concentration (a 1 or 2 per cent solution) the reader automatically erases the information encoded on the PMR label to prevent the syringe being used again with unvalidated contents.
We began with a pilot project, which led to the development of a complete system. The system was fully tested and documented for reliability and regulatory approval and was subsequently taken into high-volume manufacture by us. The Diprifusor system is now in use worldwide, with annual sales running into millions of units. We then went on to agree a formal licensing arrangement which allowed AstraZeneca to use PMR technology in the pharmaceutical sector.
The Diprifusor application illustrates how we support our clients through the full development cycle – from the adaptation of our own technology to the selection of manufacturing partners and establishing the supply chain. It also demonstrates the way in which we can take in-house IP (in this case our own, but also our clients’) to create unique and highly profitable new products.
